These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 17319915)

  • 1. Seizure-promoting effect of blood-brain barrier disruption.
    Marchi N; Angelov L; Masaryk T; Fazio V; Granata T; Hernandez N; Hallene K; Diglaw T; Franic L; Najm I; Janigro D
    Epilepsia; 2007 Apr; 48(4):732-42. PubMed ID: 17319915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans.
    Siegal T; Rubinstein R; Bokstein F; Schwartz A; Lossos A; Shalom E; Chisin R; Gomori JM
    J Neurosurg; 2000 Apr; 92(4):599-605. PubMed ID: 10761648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum transthyretin monomer as a possible marker of blood-to-CSF barrier disruption.
    Marchi N; Fazio V; Cucullo L; Kight K; Masaryk T; Barnett G; Vogelbaum M; Kinter M; Rasmussen P; Mayberg MR; Janigro D
    J Neurosci; 2003 Mar; 23(5):1949-55. PubMed ID: 12629200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery.
    Dahlborg SA; Petrillo A; Crossen JR; Roman-Goldstein S; Doolittle ND; Fuller KH; Neuwelt EA
    Cancer J Sci Am; 1998; 4(2):110-24. PubMed ID: 9532413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Reversible opening of the blood-brain barrier in the chemotherapy of malignant gliomas].
    Heimberger K; Samec P; Podreka I; Binder H; Suess E; Reisner T; Deecke L; Steger G; Hiesmayr M; Dittrich C
    Wien Klin Wochenschr; 1987 May; 99(11):385-8. PubMed ID: 3113082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience.
    Fortin D; Desjardins A; Benko A; Niyonsega T; Boudrias M
    Cancer; 2005 Jun; 103(12):2606-15. PubMed ID: 15880378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimodal investigations of trans-endothelial cell trafficking under condition of disrupted blood-brain barrier integrity.
    Marchi N; Teng Q; Nguyen MT; Franic L; Desai NK; Masaryk T; Rasmussen P; Trasciatti S; Janigro D
    BMC Neurosci; 2010 Mar; 11():34. PubMed ID: 20214812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osmotic blood-brain barrier disruption: pharmacodynamic studies in dogs and a clinical phase I trial in patients with malignant brain tumors.
    Neuwelt EA; Hill SA; Frenkel EP; Diehl JT; Maravilla KR; Vu LH; Clark WK; Rapoport SI; Barnett PA; Lewis SE; Ehle AL; Beyer CW
    Cancer Treat Rep; 1981; 65 Suppl 2():39-43. PubMed ID: 6809316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased delivery and acute toxicity of cranial irradiation and chemotherapy given with osmotic blood-brain barrier disruption in a rodent model: the issue of sequence.
    Remsen LG; McCormick CI; Sexton G; Pearse HD; Garcia R; Neuwelt EA
    Clin Cancer Res; 1995 Jul; 1(7):731-9. PubMed ID: 9816039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osmotic blood-brain barrier modification: clinical documentation by enhanced CT scanning and/or radionuclide brain scanning.
    Neuwelt EA; Specht HD; Howieson J; Haines JE; Bennett MJ; Hill SA; Frenkel EP
    AJR Am J Roentgenol; 1983 Oct; 141(4):829-35. PubMed ID: 6412531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system.
    Jahnke K; Kraemer DF; Knight KR; Fortin D; Bell S; Doolittle ND; Muldoon LL; Neuwelt EA
    Cancer; 2008 Feb; 112(3):581-8. PubMed ID: 18072268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum S100beta: a noninvasive marker of blood-brain barrier function and brain lesions.
    Kanner AA; Marchi N; Fazio V; Mayberg MR; Koltz MT; Siomin V; Stevens GH; Masaryk T; Aumayr B; Vogelbaum MA; Barnett GH; Janigro D
    Cancer; 2003 Jun; 97(11):2806-13. PubMed ID: 12767094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience.
    Angelov L; Doolittle ND; Kraemer DF; Siegal T; Barnett GH; Peereboom DM; Stevens G; McGregor J; Jahnke K; Lacy CA; Hedrick NA; Shalom E; Ference S; Bell S; Sorenson L; Tyson RM; Haluska M; Neuwelt EA
    J Clin Oncol; 2009 Jul; 27(21):3503-9. PubMed ID: 19451444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osmotic blood-brain barrier modification for the treatment of malignant brain tumors.
    Haluska M; Anthony ML
    Clin J Oncol Nurs; 2004 Jun; 8(3):263-7. PubMed ID: 15208820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of anesthetic choice, PaCO2, and other factors on osmotic blood-brain barrier disruption in rats with brain tumor xenografts.
    Remsen LG; Pagel MA; McCormick CI; Fiamengo SA; Sexton G; Neuwelt EA
    Anesth Analg; 1999 Mar; 88(3):559-67. PubMed ID: 10072006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maculopathy as a complication of blood-brain barrier disruption in patients with central nervous system lymphoma.
    Galor A; Ference SJ; Singh AD; Lee MS; Stevens GH; Perez VL; Peereboom DM
    Am J Ophthalmol; 2007 Jul; 144(1):45-49. PubMed ID: 17601426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma.
    Zylber-Katz E; Gomori JM; Schwartz A; Lossos A; Bokstein F; Siegal T
    Clin Pharmacol Ther; 2000 Jun; 67(6):631-41. PubMed ID: 10872645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood-brain barrier damage, but not parenchymal white blood cells, is a hallmark of seizure activity.
    Marchi N; Teng Q; Ghosh C; Fan Q; Nguyen MT; Desai NK; Bawa H; Rasmussen P; Masaryk TK; Janigro D
    Brain Res; 2010 Sep; 1353():176-86. PubMed ID: 20599815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-time monitoring of human blood-brain barrier disruption.
    Kiviniemi V; Korhonen V; Kortelainen J; Rytky S; Keinänen T; Tuovinen T; Isokangas M; Sonkajärvi E; Siniluoto T; Nikkinen J; Alahuhta S; Tervonen O; Turpeenniemi-Hujanen T; Myllylä T; Kuittinen O; Voipio J
    PLoS One; 2017; 12(3):e0174072. PubMed ID: 28319185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum S-100beta as a possible marker of blood-brain barrier disruption.
    Kapural M; Krizanac-Bengez Lj; Barnett G; Perl J; Masaryk T; Apollo D; Rasmussen P; Mayberg MR; Janigro D
    Brain Res; 2002 Jun; 940(1-2):102-4. PubMed ID: 12020881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.